ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Clinical Trial Protocol

He, Jinjie; Liu, Yue; Liu, Chengcheng; Hu, Hanguang; Sun, Lifeng; Xu, Dong; Li, Jun; Wang, Junye; Chen, Xiaobing; Lin, Rongbo; Jiang, Yi; Zhang, Yanqiao; Zhang, Weisheng; Cheng, Ying; Wu, Xiaohong; Fang, Mingzhi; Li, Enxiao; Xu, Ye; Chen, Ye; Li, Jiayi; Cui, Yanyan; Pan, Zhanyu; Zhang, Songnan; Yuan, Ying; Ding, Kefeng*复旦大学; 汕头大学; 江南大学; 哈尔滨医科大学; 浙江大学; 西安交通大学; 厦门大学; 1
TECHNOLOGY IN CANCER RESEARCH & TREATMENT2023DOI: 10.1177/15330338231152350
2被引7阅读
引用收藏
分享

摘要

Background: Chemotherapy combined with antivascular endothelial growth factor (VEGF) or anti-epidermal growth factor receptor monoclonal antibodies is the most promising approach to prolong survival and improve the quality of life of patients with unresectable metastatic colorectal cancer (mCRC). Anlotinib is an oral antiangiogenic tyrosine kinase inhibitor that targets VEGF receptors 1/2/3, fibroblast growth factor receptors 1-4, and platelet-derived growth factor receptors a/beta. Since anlotinib combined with oxaliplatin and capecitabine (CAPEOX) as a first-line treatment was previously shown to be effective and safe for patients with RAS/BRAF wild-type (WT) mCRC, we designed this randomized, open-label, parallel-group, non-inferiority, phase III study to evaluate the efficacy and safety of anlotinib plus CAPEOX versus bevacizumab plus CAPEOX in patients with RAS/BRAF WT mCRC. Methods/design: The primary inclusion criteria are Eastern Cooperative Oncology Group performance status 0/1, confirmed RAS/BRAF WT colorectal adenocarcinoma, and unresectable metastases assessed by a multidisciplinary team. The main exclusion criteria are as follows: high microsatellite instability or deficient mismatch repair status, resectable or potentially resectable metastases, and previous systemic therapy for mCRC. A total of 698 patients will be randomized into the anlotinib and bevacizumab groups in a 1:1 ratio. Patients will receive 4 to 8 cycles of induction therapy (CAPEOX plus anlotinib or bevacizumab), followed by maintenance treatment (capecitabine plus anlotinib or bevacizumab) until disease progression or unacceptable toxicity. Progression-free survival (PFS) assessed by an independent review committee is the primary endpoint, whereas investigator-assessed PFS, overall survival, objective response rate, disease control rate, duration of response, resection rate of liver metastases, quality of life, and safety are the secondary endpoints. Enrollment commenced in May 2021. Discussion: A prospective, randomized, phase III trial will provide a meaningful comparison of the efficacy and safety of anlotinib plus CAPEOX with standard treatment for patients with unresectable RAS/BRAF WT mCRC.

学科与关键词

关键词
metastatic colorectal canceranlotinibphase III trialfirst-line therapytyrosine kinase inhibitorvascular endothelial growth factor receptor
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
TECHNOLOGY IN CANCER RESEARCH & TREATMENT
发表日期
2023
卷期
第 22 卷
页码
15330338231152350
DOI
10.1177/15330338231152350
语言
ENGLISH
成果收录
SCIE
资助标注
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

作者

  • H

    He, Jinjie (第一作者)

    2 · zhejiang univ

  • L

    Liu, Yue

    2 · zhejiang univ

查看全部 25 位作者收起作者
  • L

    Liu, Chengcheng

    2 · zhejiang univ

  • H

    Hu, Hanguang

    2 · zhejiang univ

  • S

    Sun, Lifeng

    2 · zhejiang univ

  • X

    Xu, Dong

    2 · zhejiang univ

  • L

    Li, Jun

    2 · zhejiang univ

  • W

    Wang, Junye

    jining med univ

  • C

    Chen, Xiaobing

  • L

    Lin, Rongbo

    fujian prov canc hosp

  • J

    Jiang, Yi

    shantou univ

  • Z

    Zhang, Yanqiao

    harbin med univ

  • Z

    Zhang, Weisheng

    gansu prov peoples hosp

  • C

    Cheng, Ying

  • W

    Wu, Xiaohong

    jiangnan univ

  • F

    Fang, Mingzhi

    nanjing univ chinese med

  • L

    Li, Enxiao

    1 · xi an jiao tong univ

  • X

    Xu, Ye

    fudan univ

  • C

    Chen, Ye

    1 · henan univ

  • L

    Li, Jiayi

    1 · xiamen univ

  • C

    Cui, Yanyan

    chifeng univ

  • P

    Pan, Zhanyu

    tianjin med univ canc inst & hosp

  • Z

    Zhang, Songnan

    yanbian univ

  • Y

    Yuan, Ying

    2 · zhejiang univ

  • D

    Ding, Kefeng (通讯)

    2 · zhejiang univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417